References
- BrunelleMNJacquardACPichoudCSusceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovirHepatology2005411391815915463
- ChangTTGishRGHadziyannisSJA dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patientsGastroenterology2005129119820916230074
- ChangTTGishRGDe ManRA comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis BN Engl J Med2006a35410011016525137
- ChangTTChaoYCKaymakoglouSEntecavir maintained virologic suppression through 3 years of treatment in antiviral-naïve HBeAg(+) patients (ETV 022/901)Hepatology2006b44229A
- ColonnoRJRoseREBaldickCJHigh barrier of resistance results in no emergence of entecavir resistance in nucleoside-naïve subjects during the first two years of therapyJ Hepatol2006a44S182
- ColonnoRJRoseREPokornowskiKAssessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patientsHepatology2006b44229A
- CooksleyHHouJLVitekLImpact of nucleoside treatment on antiviral T-cell reactivity in chronic hepatitis B: major differences depending on early viral suppression, HBeAg status and HBV genotypeHepatology200644547A
- De ManRALeoniekeMMWNevensFSafety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infectionHepatology2001345788211526545
- Di MarcoVMarzanoALamperticoPClinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to LamivudineHepatology2004408839115382125
- DienstangJLSchiffERWrightTLLamivudine as initial treatment for chronic hepatitis B in the United statesN Engl J Med199934112566310528035
- DienstagJLGoldiRDHeathcoteEJHistological outcome during long-term lamivudine therapyGastroenterology20031241051712512035
- FungSKAndreonePHanSHAdefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensationJ Hepatol2005439374316168522
- FungSKChaeHBFontanaRJVirological response and resistance to adefovir in patients with chronic hepatitis BJ Hepatol2006442839016338024
- GishRGChangTTDe ManREntecavir results in substantial virologic and biochemical improvement and HBeAg seroconvertion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (Study ETV-022)Hepatology200542267A268A
- HadziyannisSJBramouTMakrisAInterferon a-2b treatment of HBeAg negative/serum HBV-DNA positive chronic active hepatitis type BJ Hepatol199011Suppl 1S113362079567
- HadziyannisSJTassopoulosNCHeathcoteEJAdefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitisBN Engl J Med2003348800712606734
- HadziyannisSJTassopoulosNCHeathcoteEJLong-term therapy with Adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis BN Engl J Med2005a35226738115987916
- HadziyannisSJTassopoulosNCChangTTLong-term Adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapyHepatology2005b42754A
- HadziyannisSJTassopoulosNCHeathcoteEJLong-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 yearsGastroenterology200613117435117087951
- LaiCLChienRNLeungNWYA one year trial of lamivudine for chronic hepatitis BN Engl J Med19983396189654535
- LaiCLRosmawatiMLaoJEntecavir is superior than lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infectionGastroenterology20021231831812454840
- LaiCLLimSGBrownNAA dose-finding study of once-daily oral Telbivudine in HBeAg-positive patients with chronic hepatitis B virus infectionHepatology2004407192615349912
- LaiCLLeungNTeoEKA 1-year trial of Telbivudine, Lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis BGastroenterology2005a1295283616083710
- LaiCLGaneELiawYFTelbivudine (LDT) vs. Lamivudine for chronic hepatitis B: first-year results from the international phase III globe trialHepatology2005b42748A
- LaiCLGaneEHsuCWTwo-years results from the globe trial in patients with hepatitis B: greated clinical and antiviral efficacy for telbivudine (LDT) vs lamivudineHepatology2006a44222A
- LaiCLShouvalDLokASEntecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis BN Engl J Med2006b35410112016525138
- LamperticoPViganoMManentiEFive years of sequential LAM to LAM +ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinomaHepatology200542582A
- LamperticoPViganoMIavaroneMLow rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 yearsHepatology200644556A
- LauGKKPiratvisuthTLuoKXPeginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis BN Engl J Med200535226829515987917
- LeeWMHepatitis B virus infectionN Engl J Med19973371733459392700
- LeungNWYLaiCLChangTTExtended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapyHepatology20013315273211391543
- LiawYFLeungNWYChangTTEffects of extended lamivudine therapy in Asian patients with chronic hepatitis BGastroenterology20001191728010889166
- LiawYFSungJJYChowWCLamivudine for patients with chronic hepatitis B and advanced liver diseaseN Engl J Med200435115213115470215
- LokASHeathcoteEJHoofnagleJHManagement of hepatitis B: 2000 summary of a workshopGastroenterology200112018285311375963
- LokASFLaiCLLeungNLong-term safety of Lamivudine treatment in patients with chronic hepatitis BGastroenterology200312517142214724824
- MaddreyWCHepatitis B: an important public health issueJ Med Virol200061362610861647
- ManesisEHadziyannisSInteferon α treatment and retreatment of hepatitis B e negative chronic hepatitis BGastroenterology2001321101911438498
- MarcellinPChangTTLimSGAdefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitisBN Engl J Med20033488081612606735
- MarcellinPLauGKKBoninoFPeginterferon alfa-2a alone, lamivudine alone and the two combination in patients with HBeAg-negative chronic hepatitis BN Engl J Med200435112061715371578
- MarcellinPChangTTLimSGIncreasing serologic, virologic and biochemical response over time to Adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patientsJ Hepatol2005422S312
- MarcellinPLauGKKFarciPThe majority of patients with HBeAg-negative chronic hepatitis B treated with Peginterferon alpha-2a (40KD) [PEGASYS] sustain responses 2 years post-treatmentJ Hepatol2006442S275
- NiederaouCHeintgesTLangeSLong term follow up of HBeAg positive patients treated with interferon alpha for chronic hepatitis BN Engl J Med1996334142278618580
- PapatheodoridisGVManesisEHadziyannisSJThe long-term outcome of interferon-a treated and untreated patients with HBeAg-negative chronic hepatitis BJ Hepatol2001343061311281561
- PapatheodoridisGVDimouELarasACourse of virological breakthroughs under long-term lamivudine in HBeAg negative precore mutant HBV liver diseaseHepatology2002362192612085368
- PapatheodoridisGVDimouEDimakopoulosKOutcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudineHepatology200542121915962291
- PetersMGHannHWMartinPAdefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitisBGastroenterology20041269110114699491
- RaptiINDimouEMitsoulaPHadziyannisSJCombination of adefovir dipivoxil with lamivudine vs adefovir alone in lamivudine-resistant HBeAg-negative chronic hepatitis B patientsHepatology2007453071317256746
- SchiffELeeWMChaoYCEfficacy and safety of entecavir (ETV) and lamivudine (LVD) in compensated, cirrhotic patients with chronic hepatitis BHepatology200542583A
- ShermanMYurdaydinCSollanoJEntecavir for the treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis BGastroenterology200613020394916762627
- ShouvalDHatzisGKitisGContinued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) hepatitis B patients (Study ETV-027)J Hepatol200644S182
- TassopoulosNCVolpesRPastoreGEfficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis BHepatology1999298899610051494
- TenneyDJLevineSMRoseREClinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudineAntimicrob Agents Chemother200448349850715328117
- ThongsawatSLaiCLGaneGTelbivudine displays consistent antiviral efficacy across patient subgroups for the treatment of chronic hepatitis B: results from the globe studyJ Hepatol200644S4916360232
- VilletSPichoudCOllivetASequential antiviral therapy leads to the emergence of multiple drug resistant hepatitis B virusHepatology200542581A
- WongDKHCheungAMO’RourkeKEffect of Alpha-Interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysisAnn Intern Med1993119312238328741
- YimHJHussainMLiuYEvolution of multi-drug resistant hepatitis B virus during sequential therapyHepatology2006447031216941700
- YurdaydinCSollanoJHadziyannisSJEntecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory HBeAg (+) chronic hepatitis B patients (ETV-026)J Hepatol200644S36